Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review

医学 肺动脉高压 科克伦图书馆 养生 加药 内科学 前列环素 曲前列环素 不利影响 联合疗法 儿科 荟萃分析
作者
Meng Li,Lin Liu,Cong Liu,Zebin Chen,Weibin Li,Xuejuan Li,Xiaopeng Ma,Yumao Zhang
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:46 (1): 59-68 被引量:4
标识
DOI:10.1016/j.clinthera.2023.09.026
摘要

To systematically evaluate the safety, dosing regimen, and efficacy of selexipag for pediatric patients with pulmonary hypertension (PH).A literature search of the electronic databases of PubMed, Embase, Web of Science, Cochrane Library, and Google Scholar was performed from inception through February 28, 2023. Two reviewers independently searched and evaluated the quality of the studies and pooled data when appropriate. Full-text articles of studies of children diagnosed with PH and treated with selexipag were eligible. Pediatric patients with PH were classified into 2 groups: the add-on therapy group, in which selexipag was used as a third therapy in addition to the baseline treatment, and the transition therapy group, in which patients were switched from parenteral prostacyclin analogs to selexipag.Fourteen studies involving 58 pediatric patients with PH were included. All studies were either case reports or case series. Overall, 30 and 28 patients were in the add-on and transition therapy groups, respectively. In both groups, selexipag was initially administered as 50-200 µg twice daily and titrated to a tolerated dosage of 200-1,600 µg twice daily. Prostacyclin analogs were simultaneously weaned for patients in the transition group. In the add-on therapy group, 16 patients (80.0%) were at low risk of the World Health Organization functional class (WHO FC I/II), 12 (76.9%) were at low risk of the 6-minute walk distance (6MWD; >350 m), and 21 (95.5%) were at low risk of the pulmonary vascular resistance index (PVRi; <20 WU/m2). Furthermore, N-terminal pro-brain natriuretic peptide and mean pulmonary arterial pressure were significantly improved. More than 70% of patients experienced common tolerable side effects, such as headache, nausea, and diarrhea. In the transition therapy group, 5 patients (55.6%) were at low risk according to WHO FC I/II, 6 (66.7%) were at low risk according to 6MWD, and 14 (87.5) were at low risk according to PVRi; however, selexipag had no significant effect on their hemodynamic parameters. Additionally, more than 80% of patients experienced no side effects.Selexipag as add-on therapy or for transition from prostacyclin analogs may have a favorable safety profile and potential efficacy for pediatric patients with PH. Further high-quality evidence of the efficacy and safety of selexipag for the treatment of pediatric PH is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
2秒前
非躺平人生完成签到,获得积分10
3秒前
3秒前
liuyepiao完成签到,获得积分10
3秒前
小蘑菇的应助被开心德地采纳,获得10
4秒前
眼睛大书兰完成签到,获得积分20
4秒前
胡闹666完成签到,获得积分10
4秒前
漂泊发布了新的文献求助10
4秒前
FashionBoy的应助被烊烊烊采纳,获得10
5秒前
乐乐的应助被WT采纳,获得10
6秒前
6秒前
yyyyy发布了新的文献求助30
6秒前
斯文思远完成签到,获得积分10
6秒前
7秒前
dlm完成签到,获得积分10
8秒前
wenjiang完成签到,获得积分10
8秒前
8秒前
烨采发布了新的文献求助10
9秒前
9秒前
9秒前
9秒前
9秒前
zumrat完成签到,获得积分20
10秒前
10秒前
月白发布了新的文献求助20
10秒前
关心完成签到,获得积分10
11秒前
深情安青的应助被开心德地采纳,获得10
11秒前
太阳照常升起完成签到 ,获得积分10
12秒前
12秒前
hu完成签到,获得积分10
12秒前
13秒前
13秒前
13秒前
彭于晏的应助被势不可挡采纳,获得10
13秒前
顺意完成签到 ,获得积分20
14秒前
yuanquaner完成签到,获得积分10
14秒前
纪十三发布了新的文献求助10
15秒前
关心发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187835
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843558
捐赠科研通 7785715
什么是DOI,文献DOI怎么找? 3435125
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482008